Doctor of Pharmacy

31/10/2024

A list of 100 important pharmacology questions and answers would be very helpful for study and review! Here’s a selection of some of the most high-yield topics in pharmacology to get started. These cover core concepts across drug mechanisms, effects, side effects, and clinical applications.
________________________________________
Basic Principles of Pharmacology
1. What is pharmacokinetics?
o Pharmacokinetics involves the absorption, distribution, metabolism, and excretion (ADME) of drugs.
2. What is bioavailability?
o Bioavailability is the fraction of an administered drug dose that reaches systemic circulation.
3. What factors affect drug absorption?
o pH, lipid solubility, blood flow, and surface area impact absorption rates.
4. What is the therapeutic index?
o The therapeutic index (TI) is the ratio between the toxic dose and the therapeutic dose of a drug. Higher TI indicates a safer drug.
5. What is first-pass metabolism?
o It’s the initial metabolism of a drug in the liver or intestines before reaching systemic circulation, reducing its bioavailability.
________________________________________
Autonomic Nervous System Drugs
6. What are the main types of cholinergic receptors?
o Nicotinic and muscarinic receptors.
7. What is the role of acetylcholine?
o Acetylcholine is a neurotransmitter involved in muscle contraction and autonomic nervous system functions.
8. What are beta-blockers and their use?
o Beta-blockers block adrenergic beta-receptors and are used for hypertension, heart failure, and arrhythmias.
9. What are the side effects of anticholinergics?
o Dry mouth, blurred vision, urinary retention, constipation, and tachycardia.
10. How do adrenergic agonists work?
• They stimulate adrenergic receptors, leading to effects like vasoconstriction, bronchodilation, and increased heart rate.
________________________________________
Cardiovascular Drugs
11. How do ACE inhibitors work?
• They block the conversion of angiotensin I to angiotensin II, lowering blood pressure.
12. What is digoxin used for?
• Treating heart failure and atrial fibrillation by increasing cardiac contractility.
13. What are the side effects of calcium channel blockers?
• Dizziness, headache, peripheral edema, and bradycardia.
14. What is the mechanism of action of statins?
• Statins inhibit HMG-CoA reductase, reducing cholesterol synthesis.
15. How do diuretics lower blood pressure?
• By promoting excretion of sodium and water, reducing blood volume and pressure.
________________________________________
Antimicrobials
16. What is the mechanism of action of penicillin?
• It inhibits bacterial cell wall synthesis, causing cell lysis.
17. What are common side effects of antibiotics?
• Nausea, diarrhea, allergic reactions, and Clostridium difficile infection.
18. What is the spectrum of action for tetracyclines?
• Broad-spectrum antibiotics effective against Gram-positive and Gram-negative bacteria.
19. What is antibiotic resistance?
• When bacteria develop mechanisms to survive despite antibiotic treatment.
20. What are aminoglycosides, and what is their primary toxicity?
• Antibiotics that can cause nephrotoxicity and ototoxicity.
________________________________________
Endocrine Drugs
21. How does insulin work in diabetes?
• Insulin facilitates glucose uptake into cells, lowering blood glucose levels.
22. What is metformin, and how does it work?
• Metformin decreases hepatic glucose production and improves insulin sensitivity.
23. What are corticosteroids used for?
• Treating inflammation, allergies, and autoimmune diseases.
24. What are side effects of long-term steroid use?
• Osteoporosis, hypertension, weight gain, and immunosuppression.
25. How do thyroid hormones affect the body?
• They regulate metabolism, growth, and energy levels.
________________________________________
CNS Drugs
26. What are benzodiazepines, and how do they work?
• They enhance GABA activity, producing sedative and anxiolytic effects.
27. What are common side effects of SSRIs?
• Nausea, s*xual dysfunction, insomnia, and increased risk of suicidal thoughts.
28. What is the mechanism of action of antipsychotics?
• They typically block dopamine receptors to reduce symptoms of psychosis.
29. What is the therapeutic use of lithium?
• Managing bipolar disorder by stabilizing mood.
30. What are stimulants used for ADHD?
• Medications like amphetamine increase dopamine and norepinephrine levels.
________________________________________
Anti-inflammatory and Pain Medications
31. What is the mechanism of NSAIDs?
• They inhibit COX enzymes, reducing prostaglandin synthesis and inflammation.
32. What are side effects of NSAIDs?
• Gastrointestinal irritation, kidney damage, and increased cardiovascular risk.
33. How does acetaminophen differ from NSAIDs?
• It lacks anti-inflammatory effects and primarily reduces fever and pain.
34. What are opioids, and how do they work?
• Opioids bind to opioid receptors, providing pain relief but with addiction potential.
35. What are the signs of opioid overdose?
• Respiratory depression, pinpoint pupils, and unconsciousness.
________________________________________
Oncology and Immunosuppressive Drugs
36. What is the mechanism of action of alkylating agents?
• They damage DNA to prevent cancer cell replication.
37. What are common side effects of chemotherapy?
• Nausea, vomiting, alopecia, and immunosuppression.
38. How do monoclonal antibodies work in cancer?
• They target specific antigens on cancer cells, enhancing immune response.
39. What is methotrexate, and what is it used for?
• An antimetabolite used in cancer and autoimmune diseases.
40. What are immunosuppressants used for?
• To prevent organ rejection and treat autoimmune diseases.
________________________________________
Other Key Drug Classes and Concepts
41. What is pharmacodynamics?
• The study of how drugs exert their effects on the body.
42. What is a prodrug?
• An inactive compound metabolized into an active drug in the body.
43. How does a competitive antagonist work?
• It binds to the same receptor site as the agonist, blocking its effect.
44. What is drug tolerance?
• A reduced response to a drug over time, requiring a higher dose for effect.
45. What are adverse drug reactions (ADRs)?
• Harmful, unintended reactions to drugs at normal doses.
________________________________________
This gives you a starting set of key questions. Expanding this list to 100 would include detailed questions on different drugs in categories like hematology, GI drugs, vaccines, and special populations (e.g., pediatrics, geriatrics). Let me know if you'd like more questions in any particular area or would like a deeper dive on certain drug classes.

31/10/2024

To become a registered pharmacist in the United States after completing a PharmD in India or Pakistan, you’ll need to go through several steps to meet U.S. licensure requirements. Here’s a general outline of the process:
1. Obtain FPGEC Certification
• Foreign Pharmacy Graduate Equivalency Examination (FPGEE): The first step is to get certified by the Foreign Pharmacy Graduate Examination Committee (FPGEC), which evaluates foreign pharmacy education equivalency.
• English Language Proficiency: You must demonstrate English proficiency, often through the TOEFL iBT exam. Required scores typically include 24 in speaking, 21 in reading, 18 in listening, and 26 in writing.
• Documentation: Submit proof of education and licensure from your home country’s pharmacy council or regulatory body.
2. Pass the FPGEE Exam
• Exam Content: The FPGEE covers basic biomedical sciences, pharmaceutical sciences, social/behavioral/administrative pharmacy sciences, and clinical sciences. You can prepare by reviewing topics covered in a typical U.S. pharmacy curriculum.
• Application Process: Once approved by the FPGEC, you can apply to take the FPGEE exam. Exams are usually conducted in the U.S. only a few times a year, so it’s important to plan accordingly.
3. Complete a Pharmacy Internship
• Internship Hours: Most states require a certain number of internship hours, which vary from state to state. Generally, 1,500 hours are required, although this can be state-specific. You may need to complete some of these hours within the U.S. under a licensed pharmacist’s supervision.
• Intern License: Many states require you to apply for an intern license to complete your internship hours, so check the specific requirements in the state where you wish to practice.
4. Pass the NAPLEX and MPJE Exams
• North American Pharmacist Licensure Examination (NAPLEX): The NAPLEX assesses your knowledge and competence as a pharmacist. It’s essential to pass this exam to become licensed.
• Multistate Pharmacy Jurisprudence Examination (MPJE): In addition to the NAPLEX, many states require the MPJE, which tests knowledge of state-specific pharmacy law.
• State-Specific Requirements: Some states may have additional requirements, such as the Compounding Exam in California. Check your state’s board of pharmacy for specific details.
5. Apply for Licensure in Your State
• Once you’ve completed the exams and internship hours, you can apply for licensure with the state board of pharmacy where you intend to practice. The application usually involves submitting proof of internship hours, exam scores, and other relevant documents.
6. Obtain Your Pharmacist License
• After your application is reviewed and approved, you will receive your pharmacist license, allowing you to practice as a registered pharmacist in the United States.
Additional Tips:
• Review State Requirements: Each state has specific licensing requirements and internship hours, so it’s essential to verify with the state board.
• Stay Updated: The process and requirements can change, so regularly check with the National Association of Boards of Pharmacy (NABP) and your state’s pharmacy board.
• Visa Considerations: For foreign pharmacists, securing a visa, such as an H-1B or green card sponsorship, is necessary to work in the U.S., and some steps may require immigration advice.
Following these steps can help you navigate the path to becoming a licensed pharmacist in the United States after earning a PharmD in India or Pakistan.

09/05/2017

09/05/2017

08/05/2017

23/03/2017

There are three different types of twins:

1. Dizygotic Twins
Monzozygotic Twins (dichorionic or monochorionic)
Polar Body Twins

1. DIZYGOTIC TWINS

Dizygotic are twins which result from the fertilization of 2 different eggs with 2 different s***ms. Dizygotic twin pairs can be girl/girl, boy/boy, or girls/boy. Other words for dizygotic twins are also fraternal or non-identical twins. The rate of spontaneous dizygotic twins varies by population. It is highest among African-Americans and lowest for Asians.

Dizygotic twin pregnancies are more likely when the following factors are present in the woman:

You are on fertility drugs
You are over 40
You are of West African descent (especially Yoruba or Hausa)
You are greater than average height and weight
You had several previous pregnancies.
You are yourself a dizygotic twin
You have a family history of dizygotic twinning.
Infertility treatments increase the rate of dizygotic twins, with about 35% of pregnancies from IVF being twin pregnancies. All dizygotic twins have separate placentas.

All dizygotic twins are dichorionic, which means they have two separate sacs and two placenta.

2. MONOZYGOTIC (MZ) TWINS

Monozygotic twins result from the fertilization of one egg and one s***m. The fertilized embryo then splits within days after fertilization resulting in two individuals which usually share the same chromosomes. Monozygotic twins are also known as identical or maternal twins.

If the embryo splits within 2-3 days after fertilization then the twins are dichorionic-diamniotic.
If the embryo splits between 3-8 days, then the twins are monochorionic-diamniotic twins.
If the embryo splits between 8-13 days, then the twins are monochorionic-monoamniotic twins.
If the embryo splits after 13 days, then the twins are monochorionic-monoamniotic conjoined twins.
The rate of monozygotic twins remains at about 1 in 333 across the globe, further suggesting that pregnancies resulting in identical twins occur randomly, though with IVF the rate of monozygotic twins is also increased.

SHARING OF THE PLACENTA IN TWINS
All dizygotic twins have two separate placentas (sometimes fused but still separate) and are in different sacs (Di-Di twins)
One third of MZ monozygotic twins have two separate placentas and sacs, similar to dizygotic twins (dichorionic or didi). With di-di MZ twins the fertilized egg has split within 2-3 days after fertilization.
2/3 of monozygotic twins share a placenta (monochorionic-diamniotic or mono-di). With mono-di MZ twins the fertilized egg has split within 3-8 days after fertilization.
About 1% of twins will share their inner sac (monochorionic, monoamniotic or mono-mono). With mono-mono MZ twins the fertilized egg has split within 8-13 days after fertilization.
In very rare cicrumstances, the fertilized eggs splits 13+ days after fertilization, and this results in conjoined twins, twins that are joined at certain body parts
DICHORIONIC VERSUS MONOCHORIONIC TWINS
When identifying twins, it is important to find out whether they are dichorionic or monochorionic. Twins that share a placenta (monochorionic) are at increased risk of certain complications such as twin-to-twin transfusion syndrome. Monochorionic twins must be watched in pregnancy much closer than dichorionic twins. Twins that are within the same sace (monochorionic-monoamniotic) have the highest risks of all twins, especially if they are conjoined twins.

Polar body twins happen very rarely, and they results from one egg fertilized by two different s***m. Polar body twinning would result in "half-identical" twins.

Zygosity
Whether twins are MZ or DZ can be determined by analysis of DNA samples from blood or other tissues. All unlike s*x twins are DZ. All monochorionic twins are MZ. Thus DNA analysis is required for the approximate 50% of twins who are like s*x with dichorionic placentas.

Pregnancy Outcomes of Monochorionic and Dichorionic Twins

07/04/2016

Therapeutic Drug Monitoring
The basic assumptions underlying therapeutic drug monitoring are that drug metabolism varies from patient to patient and that the plasma level of a drug is more closely related to the drug's therapeutic effect or toxicity than is the dosage.

Indications for drug monitoring

Drugs with a narrow therapeutic index (where therapeutic drug levels do not differ greatly from levels associated with serious toxicity) should be monitored. Example: Lithium, phenytoin, digoxin.
Patients who have impaired clearance of a drug with a narrow therapeutic index are candidates for drug monitoring. The clearance mechanism of the drug involved must be known. Example: Patients with renal failure have decreased clearance of digoxin and therefore are at a higher risk of toxicity.
Drugs whose toxicity is difficult to distinguish from a patient's underlying disease may require monitoring. Example: Theophylline in patients with chronic obstructive pulmonary disease.
Drugs whose efficacy is difficult to establish clinically may require monitoring of plasma levels. Example: Phenytoin.
Situations in which drug monitoring may not be useful

Drugs that can be given in extremely high doses before toxicity is apparent are not candidates for monitoring. Example: Penicillin.
If there are better means of assessing drug effects, drug level monitoring may not be appropriate. Example: Warfarin is monitored by measuring INR, not by serum levels.
Drug level monitoring to assess compliance is unreliable, since poor compliance cannot be distinguished from rapid metabolism without direct inpatient scrutiny of drug administration.
Drug toxicity is a clinical diagnosis. Drug concentrations within the usual therapeutic range do not rule out drug toxicity in a given patient. Example: Digoxin, where other physiologic variables (eg, hypokalemia) affect drug toxicity.
In summary, therapeutic drug monitoring may be useful to guide dosage adjustment of certain drugs in certain patients. Patient compliance is essential if drug monitoring data are to be correctly interpreted.

Pharmacokinetic Parameters

Five pharmacokinetic parameters that are important in therapeutic drug monitoring include:

Bioavailability. The bioavailability of a drug depends in part on its formulation. A drug that is significantly metabolized as it first passes through the liver exhibits a marked "first-pass effect," reducing the effective oral absorption of the drug. A reduction in this first-pass effect (eg, because of decreased hepatic blood flow in heart failure) could cause a clinically significant increase in effective oral drug absorption.

Volume of distribution and distribution phases. The volume of distribution of a drug determines the plasma concentration reached after a loading dose. The distribution phase is the time taken for a drug to distribute from the plasma to the periphery. Blood taken before completion of a long distribution phase may not reflect levels of pharmacologically active drug at sites of action. Examples: Digoxin, lithium.

Clearance. Clearance is either renal or non-renal (usually hepatic). Whereas changes in renal clearance can be predicted on the basis of serum creatinine or eGFR, there is no routine liver function test for assessment of hepatic drug metabolism.

Half-life. The half-life of a drug depends on its volume of distribution and its clearance and determines the time taken to reach a steady state level. After a period of 3 or 4 half-lives, the serum drug concentration will be 87.5% to 93.75% of the steady state value. Patients with decreased drug clearance and therefore increased drug half-life will take longer to reach a higher steady state level. In general, since non-steady state drug levels are difficult to interpret, therapeutic drug monitoring usually involves measurement of drug levels at steady state.

Protein binding of drugs. All routine drug level analysis involves assessment of both protein-bound and free drug. However, pharmacologic activity depends on only the free drug concentration. Changes in protein binding (eg, in renal failure or hypo-albuminaemia) may significantly affect interpretation of reported levels for drugs that are highly protein-bound. Example: Phenytoin. When the ratio of active to total drug is increased, the therapeutic range based on total drug level will not apply.

Drug Interactions

For patients receiving several medications, the possibility of drug interactions affecting drug metabolism must be considered. Example: Quinidine decreases digoxin clearance.

Time to sample blood to measure Drug Concentration

In general, the specimen should be drawn after steady state is reached (at least 4 half-lives after a dosage adjustment) and just before the next dose (trough level).
Peak and trough levels may be indicated to evaluate the dosage of drugs whose half-lives are much shorter than the dosing interval. Example: Gentamicin.

Drug monitoring may be performed in three main ways.

The effect of a drug may be monitored by its clinical effect eg lowering of blood-pressure, the prophylaxis of migraines or the reduction in inflammation by steroids.
The biological effect of the drug may be followed by its biochemical effects eg glucose modulation by insulin, reduction in CRP or plasma viscosity with anti-inflammatory agents, the lowering of uric acid with allopurinol or increase in prothrombin time by warfarin.
A small number of therapeutic agents may be usefully monitored by their plasma concentrations. These measurements are only of value if the plasma values reflect the biological/therapeutic effect of the drug. This value is illustrated particularly well by digoxin and phenytoin both of which have side effects that are similar to the conditions which they are used to treat (phenytoin toxicity may produce fits and digoxin toxicity may produce cardiac dysrhythmias). The measurement of other drugs such as lithium and theophylline is useful as the concentrations reflect both under- or over-therapy and also correlate with toxic biological effects.

drug half-life in adults
target plasma concentrations
timing of sample
time taken for steady state to be established in adults
route of elimination
Carbamazepine
5-27 h
4-10 mg/L
trough sample
at least 7 days
hepatic
Digoxin
40 h
0.5-1.0 microgm/L
at least 6 h after last dose
5-7 days
renal
Lithium
14-33h
0.4-0.8 mmol/L
at least 14 h after last dose
3-7 days
renal
Phenobarbitone

10-40 mg/L
trough sample
10-25 days
75% hepatic
Phenytoin
20-40 h
10-20 mg/L
trough sample
8-50 days
80% hepatic 20% renal
Theophylline
smokers 4.4 h
10-20 mg/L (adults)
5-10 mg/L (children)
trough sample
2 days
90% hepatic 10% renal
Valproate


trough sample
30-85 h

Useful Points

If patients take their digoxin or lithium tablets in the evening or at midday, then all samples taken in a morning surgery will be taken at the correct time.
Digoxin toxicity is potentiated by hypothyroidism and low concentrations of potassium.
Steady state conditions with stable plasma levels of a drug do not occur until at least 4.5 elimination half- lives have elapsed after either initiation of therapy or a change in dose. It is not possible to interpret levels measured after a shorter time as the drug is still being distributed throughout the body.

24/02/2016